EP0217916A1 - Hybrid-gene cassette vector - Google Patents
Hybrid-gene cassette vectorInfo
- Publication number
- EP0217916A1 EP0217916A1 EP86902598A EP86902598A EP0217916A1 EP 0217916 A1 EP0217916 A1 EP 0217916A1 EP 86902598 A EP86902598 A EP 86902598A EP 86902598 A EP86902598 A EP 86902598A EP 0217916 A1 EP0217916 A1 EP 0217916A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- gene
- vector
- human
- derived
- hybrid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000013598 vector Substances 0.000 title claims abstract description 189
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 410
- 239000012634 fragment Substances 0.000 claims abstract description 183
- 108091026890 Coding region Proteins 0.000 claims abstract description 87
- 108020004414 DNA Proteins 0.000 claims abstract description 58
- 238000005215 recombination Methods 0.000 claims abstract description 58
- 230000006798 recombination Effects 0.000 claims abstract description 57
- 241000701959 Escherichia virus Lambda Species 0.000 claims abstract description 28
- 239000013599 cloning vector Substances 0.000 claims abstract description 25
- 108700026244 Open Reading Frames Proteins 0.000 claims abstract description 16
- 108091092195 Intron Proteins 0.000 claims abstract description 8
- 241000282414 Homo sapiens Species 0.000 claims description 146
- 239000013612 plasmid Substances 0.000 claims description 122
- 210000004027 cell Anatomy 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 56
- 108700005091 Immunoglobulin Genes Proteins 0.000 claims description 34
- 108091007433 antigens Proteins 0.000 claims description 32
- 241001529936 Murinae Species 0.000 claims description 31
- 239000000427 antigen Substances 0.000 claims description 30
- 108700024394 Exon Proteins 0.000 claims description 29
- 102000036639 antigens Human genes 0.000 claims description 29
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 claims description 27
- 239000003550 marker Substances 0.000 claims description 26
- 102000004190 Enzymes Human genes 0.000 claims description 21
- 108090000790 Enzymes Proteins 0.000 claims description 21
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 claims description 17
- 238000011144 upstream manufacturing Methods 0.000 claims description 16
- 108091060545 Nonsense suppressor Proteins 0.000 claims description 15
- 101150076359 Mhc gene Proteins 0.000 claims description 11
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 10
- 108060003951 Immunoglobulin Proteins 0.000 claims description 10
- 102000018358 immunoglobulin Human genes 0.000 claims description 10
- 230000010076 replication Effects 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 7
- 108700026220 vif Genes Proteins 0.000 claims description 5
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 claims description 4
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 claims description 4
- 239000002131 composite material Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 230000007505 plaque formation Effects 0.000 claims description 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 2
- 101150017040 I gene Proteins 0.000 claims 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 101710172711 Structural protein Proteins 0.000 claims 1
- 101150034785 gamma gene Proteins 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 210000004754 hybrid cell Anatomy 0.000 claims 1
- 238000002372 labelling Methods 0.000 abstract 3
- 101150063325 ab gene Proteins 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 77
- 238000010276 construction Methods 0.000 description 44
- 230000029087 digestion Effects 0.000 description 29
- 239000000523 sample Substances 0.000 description 28
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 24
- 210000004602 germ cell Anatomy 0.000 description 24
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 16
- 210000004408 hybridoma Anatomy 0.000 description 15
- 238000001962 electrophoresis Methods 0.000 description 12
- 239000011543 agarose gel Substances 0.000 description 11
- 238000010828 elution Methods 0.000 description 11
- 108091008146 restriction endonucleases Proteins 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 9
- 238000002054 transplantation Methods 0.000 description 9
- 102000012410 DNA Ligases Human genes 0.000 description 8
- 108010061982 DNA Ligases Proteins 0.000 description 8
- 108700005092 MHC Class II Genes Proteins 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 8
- 102000054766 genetic haplotypes Human genes 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 108700005089 MHC Class I Genes Proteins 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 241001288713 Escherichia coli MC1061 Species 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000003623 enhancer Substances 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 101100297420 Homarus americanus phc-1 gene Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 108700025695 Suppressor Genes Proteins 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 101150013834 B' gene Proteins 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010067802 HLA-DR alpha-Chains Proteins 0.000 description 2
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
- 101000574060 Homo sapiens Progesterone receptor Proteins 0.000 description 2
- 101000738977 Homo sapiens Reverse transcriptase/ribonuclease H Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 101100058506 Mus musculus Bloc1s5 gene Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 101710160107 Outer membrane protein A Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000000211 autoradiogram Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 238000013492 plasmid preparation Methods 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- -1 tetracyline Chemical compound 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101100508840 Daucus carota INV3 gene Proteins 0.000 description 1
- 101150067056 Epsilon gene Proteins 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 108700029228 Immunoglobulin Heavy Chain Genes Proteins 0.000 description 1
- 108700029227 Immunoglobulin Light Chain Genes Proteins 0.000 description 1
- 102000012960 Immunoglobulin kappa-Chains Human genes 0.000 description 1
- 108010090227 Immunoglobulin kappa-Chains Proteins 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 101000914492 Mus musculus B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- SWPYNTWPIAZGLT-UHFFFAOYSA-N [amino(ethoxy)phosphanyl]oxyethane Chemical compound CCOP(N)OCC SWPYNTWPIAZGLT-UHFFFAOYSA-N 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 101150087698 alpha gene Proteins 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010359 gene isolation Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000002980 germ line cell Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to a cassette vector for use in constructing hybrid genes in particular, a family of hybrid genes which are polymorphic in one gene region.
- Functional antibody molecules are composed of two light (L) chains and two heavy (H) chains, arranged in heavy/light pairs as H 2 L 2 tetramers. Each light and heavy chain contains a variable (V) region which is responsible for the antibody's antigen specificity and a constant (C) region which contributes receptor and structural functions.
- V variable
- C constant
- the immune response in humans against a. foreign (mouse) monoclonal antibody is directed largely against the antibody's light- and heavy-chain constant regions
- a human/mouse hybrid antibody having mouse variable regions and human constant regions would largely neutralize the antibody's ability to provoke an undesired immune response when administered over long periods for therapeutic use.
- the hybrid antibody could be constructed with specificity against any given antigen, since the antigen-specific variable regions of the antibody would be derived from antibodies generated in mice.
- Hybrid human antibodies whose variable and constant regions are derived from different antibody classes would also have important therapeutic uses.
- an IgM antibody is directed against red blood cell antigens, causing agglutination and destruction.
- a hybrid human monoclonal antibody whose variable IgM region is directed against red blood cells, but which has, for example, an IgG constant region, should be able to compete with the IgM antibody for binding to red blood cell antigen sites, thus blocking IgM antibody attachment to the red blood cells, without itself producing the undesired hemolytic response.
- non-complement fixing antibodies could be converted to complement-fixing antibodies to increase their effects in fighting infectious diseases or malignancies.
- hybrid transplantation antigens Another type of hybrid immunological structure which would be expected to have important medical uses includes hybrid transplantation antigens.
- the transplantation and immune response antigens are important in numerous aspects of the immune system, including transplantation rejection, and, more generally, recognition of cell-bound antigens by cytotoxic T-cells.
- the human transplantation antigens are coded by class I and class II genes of the human major histocompatibility complex (MHC), also referred to as the human leukocyte antigens (HLA), contained in a
- MHC human major histocompatibility complex
- HLA human leukocyte antigens
- each gene is composed of a series of coding regions (exons) each separated by noncoding (intron) regions of variable length.
- the first three exons in class I genes and the first two exons in class II genes are highly polymorphic, and are primarily responsible for the variations in transplantation antigenicity seen among individuals in a population (references 2 and 3).
- the remaining coding regions in the class I and class II genes are associated with inter-chain interactions, transmembrane and other structural or effector functions of the antigens.
- the class I and class II genes of the HLA antigens correspond to a number of class I and class II genes in the mouse MHC. Comparative studies on the two systems has shown correspondence between a number of human and mice class I and II genes (see, for example, references 2-4).
- the gene correspondence, and in particular the structural and functional homology between the analogous human HLA and mouse MHC genes, would allow construction of hybrid genes containing human polymorphic coding regions, such as the first three exons of the class I human genes or the first two exons of the class II gene, and complementary mouse nonpolymorphic regions.
- hybrid class I and II HLA/MHC genes could be constructed in a manner similar to that described above for constructing hybrid antibody genes, in which isolated cloned human and mouse genes would be spliced together at suitable intron regions and successful transformants selected and confirmed as to gene construction.
- This method would suffer from the same limitations mentioned above, and generating a family of hybrid histocompatibility complex genes, each member having a different HLA polymorphic region, would be correspondingly difficult.
- hybrid immunological structures including hybrid antibodies and transplantation antibodies, but also including other structures, such as T-cell receptor antigens, which are also characterized by families of genes composed of highly polymorphic gene-coding regions joined to relatively non-polymorphic regions. Accordingly, it would be highly desirable, as part of a procedure for constructing families of hybrid immunological structures, to provide a method by which families of hybrid genes could be readily generated.
- Another object of the invention is to provide a novel cassette vector for use in the hybrid gene-construction method.
- a more specific object of the invention is to provide such method and cassette vector having the following advantages in the construction of a family of hybrid genes:
- hybrid genes are constructed from DNA fragment libraries rather than from isolated cloned genes
- hybrid genes are formed without gene cutting and splicing manipulations.
- the cassette vector of the invention is intended for use in constructing one or preferably a family of hybrid A i -B' genes, where:
- a i is a polymorphic coding region derived from an A i -B i gene in a family of A-B genes;
- B' is derived from a selected A'-B' gene
- a i and A' and B i and B' are structurally and functionally homologous gene regions; and (d) A and B coding regions and the A' and B' coding regions are separated by introns I and I'. respectively.
- the vector includes: (1) a selectable-marker gene which permits selection of a genomic library clone which acquires the marker gene by recombination with the vector, (2) the B' coding region, and (3) located adjacent the coding region, a gene fragment derived from an intron having base-sequence homology with the A/B intron I of a gene from the A-B gene family.
- the selectable-marker gene is a suppressor tRNA gene which allows expression of amber-mutation structural genes in a phage clone which acquire the cassette vector by recombinat.ion.
- the B' coding region includes the constant coding region of a preferably human A-B gene of a selected class, i.e., either the ⁇ or ⁇ light-chain class or the ⁇ , ⁇ , ⁇ , ⁇ 1. ⁇ 2, ⁇ 3, ⁇ 4, or ⁇ heavy-chain classes.
- the A i -B i gene used in constructing the hybrid gene is derived from a cell capable of producing antibody specific against a selected antigen, typically a mouse hybridoma cell line.
- the A i -B i gene can also be from a human hybridoma cell line when it is desired to change the class of antibody produced by that hybridoma.
- an hybrid immunoglobulin gene there is first produced a library of genomic DNA derived from the cell known to contain the desired A i -B i in functional
- the DNA library fragments some of which contain the A i variable coding region of the A i -B i gene, and the adjacent downstream intron, are introduced into a recombination positive host which harbors the cassette vector of the invention.
- a recombination event between an A i -intron genomic library fragment and the cassette vector leads to incorporation of the vector into the genomic clone, with the B' coding region in the cassette vector positioned adjacent the A i gene in the cloning vector, and remaining portions of the cassette vector located between the intron region where recombination has occurred and portions of the A i -B i gene which are downstream of the region of recombination.
- B' coding regions in the recombined gene are separated by a "composite" intron which may contain an immunoglobulin enhancer segment acquired from the cassette vector by the recombination event.
- a "composite" intron which may contain an immunoglobulin enhancer segment acquired from the cassette vector by the recombination event.
- the acquisition by the cloned gene of the selectable marker in the cassette vector e.g., a suppressor-tRNA gene, allows the vector containing the desired hybrid gene to be selected when grown in a suitable selection host, e.g., a suppressor-minus bacterial host.
- the cassette vector designed for constructing human/mouse transplantation antigen genes contains a B' coding region derived from the predominantly non-polymorphic exons of a selected mouse MHC gene.
- the intron gene fragment is derived from the intron between the homologous B i coding region in a corresponding human MHC gene, and the complementary A i , predominantly polymorphic, coding region in the gene.
- To construct a hybrid histocompatibility antigen gene there is first provided a genomic DNA library derived from the cells of an individual having particular class I or class II gene polymorphisms.
- the cloned DNA library fragments are introduced into a recombination-positive host also harboring the cassette vector.
- a recombination event between the homologous intron regions in the cassette vector and the intron region of the A i -containing insert leads to incorporation of the cassette vector into the cloned B' gene with the B' nonpolymorphic coding regions in the vector being positioned adjacent and downstream of the A i human polymorphic region of the phage.
- the invention also includes hybrid antibody and cell-surface antigen genes containing the composite intron formed by the recombination event between the cloning and cassette vectors, and hybrid histocorapatibility antigens formed in accordance with the method of the invention.
- Figure 1 illustrates a scheme for constructing a cassette vector of the invention
- Figure 2 illustrates the recombination event between homologous intron regions in an A i -B i gene carried in a ⁇ phage vector, and the cassette vector of Figure 1, to form a hybrid A i -B' gene
- Figure 3 illustrates the construction of a cassette vector for use in preparing a hybrid light-chain gene with a human ⁇ constant region coding sequence
- Figure 4 shows electrophoresis patterns obtained for the cassette vector of Figure 3, following digestion with Xbal and Hindlll (A) or with EcoRI (B);
- Figure 5 illustrates the recombination event between the IS2 regions of a mouse germ-line ⁇ gene contained in a ⁇ phage and in the cassette vector of Figure 3, to form a hybrid light-chain gene whose sequences upstream of the IS2 region are derived from a mouse ⁇ gene and whose constant coding region is derived from the human constant coding region of a human ⁇ chain gene contained in the cassette vector;
- Figure 6 shows an autoradiogram pattern of the hybrid ⁇ gene from Figure 5, following digestion with EcoRI and hybridization to a ⁇ anl3 probe;
- Figure 7 illustrates the steps in the construction of a cassette vector for use in preparing a hybrid heavy-chain gene containing a human IgG 4 heavy-chain coding region
- FIG 8 shows electrophoresis patterns obtained for the cassette vector of Figure 7, following digestion with PstI;
- Figure 9 illustrates the recombination event between the IS2 regions of a mouse germ-line ⁇ gene contained in a ⁇ phage and in the cassette vector of Figure 7, to form a hybrid heavy-chain gene whose upstream sequences are derived from mouse ⁇ gene, and whose constant coding region is derived from the human constant region of a human IgG chain gene contained in the cassette vector;
- Figure 10 illustrates the steps in constructing a cassette vector for preparing a hybrid human DR ⁇ /mouse I-E ⁇ immune response gene
- Figure 11 illustrates the recombination event between a human DR ⁇ gene contained in a ⁇ phage and the cassette vector of Figure 9, to form a hybrid DR ⁇ /I-E ⁇ gene.
- Figure 12 illustrates the construction of the phage vector ⁇ GLla described in Example VII from ⁇ EMBL 3 and ⁇ Ch4a.
- Figure 13 is a restriction map of the ⁇ light chain cassette vector ⁇ LC ⁇ .Notl, described in
- Figure 14 is a restriction map of the ⁇ 4 heavy chain cassette vector irHC ⁇ 4 .NotI, whose construction is described in Example III.
- Figure 15 illustrates the construction of the ⁇ 1 heavy chain cassette vector ⁇ HC ⁇ 1 .NotI described in Example VIII.
- Figure 16 illustrates the construction of the ⁇ 3 heavy chain cassette vector ⁇ HC ⁇ 3 .NotI described in Example IX.
- Figure 17 illustrates the construction of the isotype switching cassette vector ⁇ SWMG 3 .NotI described in Example X.
- Figure 18A and B illustrate the structure of the isotype switching cassette vectors ⁇ SWMG and ⁇ SWMG 1 .NotI, respectively, described in Example XI.
- Figure 19 is a restriction map of a region of the mouse unrearranged light chain gene from which the J ⁇ and -J ⁇ probes are isolated and employed in Example XII.
- Figure 20 is a restriction map of a region of the mouse unrearranged heavy chain gene from which the
- Figure 21 illustrates the recombination between the light chain cassette vector of Figure 13 and a murine anti-Leu3 light chain gene cloned in ⁇ GLla to form a hybrid mouse/human light chain gene in plasmid ⁇ Leu-3.LC as described in Example XII.
- FIG. 1 illustrates a method which is generally applicable to the construction of the cassette vector of the invention.
- a plasmid used in the vector construction contains (1) an origin of replication (ori), (2) a selectable-marker gene (sup), and (3) a polylinker (PL) containing a number of preferably unique restriction sites at which additional gene fragments can be inserted.
- the origin of replication is one which allows plasmid replication in a host which also harbors cloned library gene fragment(s) with which the cassette vector recombines, in forming the hybrid gene, as will be described below.
- the origin of replication typically is a ColEl replicon which permits replication in a variety of ⁇ -infectable bacterial hosts, such as E. coli.
- the cassette and cloning vector plasmids are designed with different (non-homologous) replicons which allow the two plasmids to replicate within a common host without recombination at the replicon sites.
- a two-plasmid system of this type is described in reference 5.
- the selectable-marker gene is preferably a suppressor-tRNA gene (supF) which allows expression of amber-mutated genes in the cloned library vector (s) which acquires the supF gene by recombination.
- a suppressor-tRNA gene is its relatively small size, typically 200 to 300 bp, its well-studied characteristics, and its versatility in vector systems having different types of amber mutations. For example, in ⁇ -phage library vectors carrying amber-mutated structural genes, acquisition by the phage of the suppressor gene allows recombination selection based on ⁇ growth in a suppressor-minus host.
- the acquisition of the suppressor allows plasmid selection based on growth in the presence of the antibiotic.
- the cassette vector selectable marker gene is to be acquired by a plasmid library vector, the marker gene itself may be an antibiotic resistance gene.
- An alternative type of selectable marker possible for use with a ⁇ library vector is based on the increase in phage size produced by recombination between the ⁇ and a relatively large cassette vector.
- the phage is constructed in size so that it is conditionally viable, e.g., can be killed under certain chemical medium conditions. With the recombination event, the phage acquires an additional length of the cassette vector which allows it to survive readily under such conditions.
- a preferred plasmid for use in constructing the cassette vector of the invention is a ir plasmid of the type described in reference 6.
- a plasmid similar to the one described in reference 6 is shown at the upper right in Figure 3, and includes a 645 bp replicon derived from pMBl, a 198 bp tyrosine tRNA amber-suppressor gene (supF), and a 49 bp polylinker segment which includes the restriction sites indicated in the expanded scale.
- a B' coding region which will contribute the B' coding portion and the 5' I-B' junction of a hybrid A i -B' gene formed using the vector, is inserted into a suitable site in the plasmid mentioned above.
- the B' coding region includes the constant coding region of a selected immunoglobulin gene class and source, where the cassette vector is used in preparing hybrid immunoglobulin genes.
- the B' coding region typically includes one or more of the non-polymorphic exons from a selected histocompatibility gene.
- the B' coding region is derived preferably from an isolated A'-B' gene, or B'-containing gene fragment, or cloned B' cDNA.
- a suitable cloned genomic or cDNA B' coding region can be obtained by standard methods.
- a large number of human and raurine immunoglobulin genes or gene fragments have been cloned, and complete or partial restriction maps and, in some cases, partial gene sequences have been reported for a number of these. Up-to-date restriction site and coding information on cloned immunoglobulin genes can be obtained from the
- HUMIGCA2 HUMAN IG GERMLINE HEAVY CHAIN D-REGION GENE. 01.
- HUMIGCB8 HUMAN IG GERMLINE H-CHAIN J-MU-DELTA REGION: MU-MEMBRANE EXON M1
- HUMIGCC4 HUMAN IG GERMLINE G-E-A REGION A: GAMMA-1 CONSTANT REGION.
- HUMIGCC8 HUMAN IG GERMLINE G-E-A REGION A: ALPHA-1 CONSTANT REGION.
- HUMIGCD1 HUMAN IGGERMLINE H-CHAIN G-E-A REGION B: GAMMA-2 CONSTANT REGION.
- HUMIGCD2 HUMAN IGGERMLINE H-CHAIN G-E-A REGION B: GAMMA-4 CONSTANT REGION.
- HUMIGHAE2 HUMAN IG ACTIVE HEAVY CHAIN EPSILONI GENE. CONSTANT REGION.
- HUMIGKC1 HUMAN IG GERMLINE KAPPA L-CHAIN. J-REGION GENES J1-J5.
- HUMIGKC2 HUMAN IGGERMLINE KAPPA L-CHAIN PARTIAL J-C INTRON.
- HUMIGKC3 HUMAN IG GERMLINE KAPPA L-CHAIN. CONSTANT REGION ( INV3 ALLELE).
- HUMIGLAA HUMAN IG ACTIVE LAMBDA L-CHAIN CONSTANT REGION GENE. KE- OZ+.
- HUMIGLC1 HUMAN IG GEFMLINF LAMBDA L-CHAIN C-REGION ISOTYPE MCG.
- HUMIGLC2 HUMAN IGGERMLINE LAMBDA L-CHAIN C-REGION 2.
- HUMIGLC3 HUMAN IGGERMLINE LAMBDA L-CHAIN C-RFGION 3.
- H UMMHOCI A HUMAN MHC CLASS II HLA-DCl-ALPHA GENE (DRWG.WG). MRNA.
- HUMMHORS1 HUMAN HLA-DR ALPHA-CHAIN (CHAIN-P34) GENE.
- HUMMHDRS2 HUMAN HLA-DR ALPHA-CHAIN (CHAIN-P34) GENE.
- HUMMHDSA HUMAN HLA-DS ALPHA-CHAIN MRNA.
- HUMMHDXA1 HUMAN MHC CLASS II HLA-DX-ALPHA GENE (DR4.WG).
- HUMHHDXA2 HUMAN MHC CLASS II HLA-DX-ALPHA GENE (DR4.WG). EXON 2.
- MUSIGE1 MOUSE IG GERMLINE EPSILON GENE AND SECRETED TAIL.
- MUSIGASANB MOUSE IG ALPHA S REGION FROM MG03 AFTER NON-PRODUCTIVE S-S.
- MUSIGDJC31 MOUSE IG GERMLINE D-J-C REGION: S-GAMMAZA REGION. PART B.
- MUSIGDJC38 MOUSE IG GERMLINE D-J-C REGION: GAMMAZA MEMBRANE EXON REGION.
- MUSJGL1A1 MOUSE IG LAMBDA1 ACTIVE GENE VARIABLE/JOINING REGION.
- MUSIGL1A2 MOUSE IG LAMBDA1 ACTIVE GENE CONSTANT REGION.
- MUSIGL2A1 MOUSE IG LAMBDA2 ACTIVE GENE VARIABLE/JOINING REGION.
- MUSIGL2A2 MOUSE IG LAMBDA2 ACTIVE GENE: CONSTANT REGION.
- MUSMH MOUSE MHC CLASS I TRANSPLANTATION ANTIGEN (HAPLOTYPE 0). MRNA.
- MUSMHD3 MOUSE MHC CLASS I GENE.
- CLONE MUSMHIEAO MOUSE MHC CLASS II H2-IE-ALPHA GENE (HAPLOTYPE D).
- MUSMHKB MOUSE MHC CLASS I H2-K GENE ( HAPLOTYPE B). MRNA. CLONE PH202.
- MUSMHLD2 MOUSE MHC CLASS I H2-L GENE ( HAPLOTYPE D ). EXONS 4-8. Methods for isolating cloned A'-B' genes or B' -containing gene fragments or obtaining cDNA clones have been described exhaustively, and appropriate references can be obtained for each gene of interest from the data base information noted above. In many cases, cloned fragments and/or probes suitable for isolating the cloned fragments are available.
- probes or cloned gene fragments are not readily available, the latter may be obtained, conventionally, by first constructing a synthetic oligonucleotide corresponding in sequence to a sequenced portion of the gene, then using the probe to identify suitable cloned gene fragments.
- restriction maps of regions of interest in the cloned genes are not available, these may be constructed by conventional restriction mapping methods, such as described in reference 7.
- the B'-coding region is excised, conventionally, by treating the B'-region cloning vector with one or more selected restriction endonucleases.
- Suitable restriction sites can be determined from restriction maps of the A'-B' gene, obtained from published sources, data base information, or by conventional restriction analysis of the cloned B' fragment.
- the B' gene is preferably excised near its 5' end, in a region of the 5'-adjoining intron, and at its 3' end, at a location downstream of post-transcriptional and post-translational signals, i.e., downstream of the gene's polyadenylation site.
- the 5' cleavage site is in the IS2 intron between the gene's variable and constant regions.
- the 5' cleavage site is in the intron between the gene's polymorphic and non-polymorphic exons, e.g., in the murine MHC I-A or I-E, ⁇ or ⁇ gene, in the intron between exons 2 and 3.
- Example I describes the construction of a cassette vector whose B' coding region is derived from human germ-line ⁇ gene.
- the construction of a cassette vector whose B' region is derived from the constant-coding region of a human germ-line ⁇ 4 immunoglobulin chain gene is detailed in Example III.
- Example V describes the construction of a cassette vector which carries, as the B' coding region, the major portion of intron 2 for the murine I-E ⁇ chain through to the downstream region encoding beyond the polyadenylation site for the gene.
- the gene can be cloned from many murine genomic libraries, and can be isolated following the procedure of reference 8.
- the cassette plasmid is digested with one or more selected restriction endonucleases, and preferably at unique restriction sites contained in a polylinker region of the plasmid, to linearize the plasmid at a site suitable for insertion of the isolated B' fragment.
- the sites at which the B' fragment and/or the plasmid may be cleaved are preferably sites which will provide proper orientation of the B' fragment in the plasmid by sticky-end ligation at one or both fragment ends.
- the linearized plasmid and isolated B' fragment are ligated conventionally under sticky-end and/or blunt-end conditions, and successful transformants are selected using standard procedures.
- the host preferably includes a second plasmid having one or more amber-mutated antibiotic genes which are expressed only in the presence of the plasmid suppressor-tRNA gene.
- a selection system is described in Examples I, III, and V.
- the plasmid obtained is designated pB' in Figure 1.
- an intron gene fragment is introduced into the plasmid adjacent the B' coding fragment.
- the intron gene fragment is homologous to an intron region in a gene which contains the complementary A i coding region of the hybrid A i -B' gene which is to be prepared using the cassette vector. More specifically, the gene fragment has sufficient homology with an intron region of the A i -containing gene to allow a recombination between the two intron regions in a recombination-competent host system.
- the extent of homology between the cassette vector's gene fragment and that of the A i -containing gene intron must be at least about 90% in order for such recombination to occur efficiently, although the extent of homology required becomes greater for relatively short homologous regions.
- the intron gene fragment is derived from intron between the A and B coding regions of a gene which is itself a member of the family of A-B genes which contains the A i -B i gene (which contributes the A i coding region to the hybrid A i -B' gene).
- A-B gene families used in the invention include, but are not limited to: a.
- the family of human immunoglobulin light-chain genes including the several known ⁇ and ic genes, where A and B are variable- and constant-coding regions, respectively.
- the intron gene fragment is derived from the IS2 region between the variable and constant coding regions of the gene, and may include the enhancer element contained in the IS2 region, as described below.
- the intron is also preferably derived from the IS2 region which, in an unrearranged immunoglobulin gene, is upstream of the switch signal at which class switching occurs.
- the intron gene fragment is, of course, derived from the intron between the adjacent exons in the selected A and B coding regions.
- the sources and methods for obtaining suitable isolated cloned genes or gene fragments containing the IS2 portion of the immunoglobulin genes, or the desired intron in a histocompatibility gene are similar to those described above with respect to gene fragments containing a B' coding gene fragment, as are sources for and methods of obtaining restriction maps of the gene regions.
- the cloned intron-containing gene or gene fragment is treated with one or more selected restriction endonucleases to excise a desired intron gene fragment.
- the size and location of the fragment which is excised will depend on a variety of considerations, including the availability of suitable restriction sites in the intron region.
- the intron fragment derived from an immunoglobulin-chain A-B family preferably includes the enhancer element in the IS2 gene region. This element has been shown in both human and mouse immunoglobulin genes to contribute to efficient transcription of the immunoglobulin gene in same-species B-lineage cells (reference 9-12).
- the total length of the intron fragment is preferably between about 60 and 1000 bp, and the fragment must be free of repetitive sequences if unwanted recombination events are to be avoided. Methods for screening gene fragments for the presence of repetitive sequences are well known. Finally, the gene fragment may be cut at sites which facilitate insertion into the B'-containing (pB') plasmid with proper orientation.
- Example I illustrates the construction of a cassette vector having a 1 kb IS2 region derived from a Hindlll/BamHI segment of mouse ⁇ gene
- Example III describes the construction of a heavy-chain cassette vector in which the gene fragment is a 1 kb Xbal segment of a mouse ⁇ gene. Both of the IS2 regions include enhancer regions from the respective genes.
- Example V below describes construction of a hybrid MHC-class II heavy-chain cassette vector containing a 272 bp gene fragment from the 5' portion of the second intervening sequence from a human DR- ⁇ chain obtained in accordance with reference 13.
- the pB' plasmid constructed as above, is linearized by digestion with one or more restriction endonucleases which preferably cleave the plasmid only in the polylinker and/or intron portion of the B' segment upstream of the B' coding region.
- the linearized plasmid is isolated, conventionally, and ligated to the isolated intron gene fragment from above using conventional sticky-end and/or blunt-end ligation conditions, to insert the intron gene fragment adjacent the 5' end of the B' coding fragment.
- Successful transformants are selected on a suitable host under growth conditions which require the presence of the cassette vector's selectable-marker gene, as discussed above.
- the desired construct, indicated at pIB' at the bottom in Figure 1, can be confirmed by restriction analysis.
- A. coding region to the hybrid gene For example, in the construction of a human/mouse hybrid immunoglobulin gene whose variable coding region is derived from mouse gene, the gene source is typically a mouse hybridoma cell line prepared to produce antibodies against a selected antigen. In constructing a hybrid histocompatibility antigen gene, a common source of genomic DNA material is any EBV-transformed lymphoblast line obtained from the subject of interest by standard means (references 14-16).
- the cells which provide the source of A i -B i gene are cultured under standard conditions, and genomic DNA is extracted from the cells and partially digested with a suitable restriction endonuclease, such as Sau3a, according to known procedures.
- the restriction digest pieces are ligated into the vector, followed by plating on an appropriate bacterial host. Methods for forming such genomic libraries are well known and are detailed, for example, in reference 17.
- a preferred cloning vector for the genomic DNA fragments is a ⁇ phage, such as a Charon 4A phage, containing A am B am structural genes necessary for ⁇ packaging and growth.
- the ⁇ structural genes code for incomplete proteins and the phage is unable to form plaques when plated on a suppressor-minus host.
- the suppressor tRNA gene in the cassette vector is able to repress the phage amber mutation, allowing selection, on the basis of plaque formation, of those phage which have acquired the cassette vector.
- recombination-selection method will be described herein with particular reference to a phage- ⁇ /suppressor tRNA system of this type, it is understood that other recombination selection systems, such as one in which an antibiotic resistance gene in a cassette vector is acquired by a cloning plasmid, allowing growth of the cloning plasmid in an antibiotic selection medium could be carried out readily by those skilled in the field.
- the desired recombination event between the cassette vector and cloning vector with a homologous intron region will occur, typically at a frequency of between about 10 -4 and 10 -2 .
- the recombination event places the B' coding region in the cassette vector adjacent the A i coding region in the cloning vector to form the desired hybrid A i -B' gene, and places the entire cassette vector fragment between the original A i and B i coding regions in the coding vector.
- the expanded phage population is plated on a suppressor-minus host which allows plaque formation only in those phage which have acquired the cassette vector by the recombination event.
- the plaques may be repassaged on a suitable host one or more times to increase the total amount of hybrid-gene phage, preferably on a suppressor-minus host, to prevent back-recombination events.
- the construction of the hybrid-gene phage may be confirmed by restriction analysis to eliminate hybrid genes resulting from cassette vector recombination with inactive or incomplete A i -containing gene fragments.
- the ⁇ phage vector used to construct the genomic library is modified to contain two restriction sites recognized by an enzyme, such as Notl, Sfil or Xhol, that rarely recognizes a restriction site in the source of the A i -B i or A'-B' genes.
- an enzyme such as Notl, Sfil or Xhol
- These two identical restriction sites for example both NotI, are inserted at either end of the ⁇ phage's "stuffer"fragment and flanking one or more pairs of more frequently recognized restriction sites, such as BamHI, Hindlll and EcoRI (see Figure 12).
- it is an enzyme that cuts the genomic DNA at enough sites to be suitable for use in making a genomic library. Even more preferably, it is the enzyme used to make the library.
- FIG. 21 shows such a construction where the common EcoRI sites and rare NotI sites flank a genomic clone of a murine light-chain immunoglobulin gene.
- the restriction site should be located in the cassette vector adjacent to the 5' end of segment I and with neither the selection marker (e.g., SupF), nor the cassette's origin of replication located between the rare restriction site and I.
- the restriction site would be located in the segment between sup and I.
- a preferred ⁇ vector for library construction is ⁇ GLla described in Example VIII and shown in Figure 12.
- the use of this ⁇ with a genomic insert in recombination with a cassette vector containing the same rare restriction site (NotI) is described in Example XII and shown in Figure 21.
- a i is a polymorphic coding region derived from an A i -B i gene in a family of A-B genes;
- B' is derived from a selected A'-B' gene
- a i and A and B i and B' are structurally and functionally homologous gene regions
- a and B coding regions and A' and B' coding regions are separated by introns I and I', respectively.
- the I and I' introns may be, but are not necessarily, homologous.
- a cassette vector whose B' coding region is a human immunoglobulin ⁇ -chain coding region, and whose intron gene fragment is from one of the family of murine light-chain genes, can be used to form both mouse ⁇ - and ⁇ -variable/human- ⁇ hybrid genes.
- a cassette vector whose B' coding egion is a human ⁇ 1 -gene coding region and whose intron gene is derived from a gene portion 5' with respect to the switch region from one of the family of murine heavy-chain genes, may be used in forming mouse variable genes from ⁇ , ⁇ , ⁇ , ⁇ 1 , ⁇ 2 , ⁇ 3 , ⁇ 4 , and ⁇ /human constant ⁇ 1 hybrid genes.
- the vector may be used in preparing human variable ⁇ , ⁇ , ⁇ . ⁇ 1 , ⁇ 2 , ⁇ 3 , ⁇ 4 , and ⁇ /human constant region hybrid genes.
- Examples II and IV describe the construction of mouse-variable/human-constant light- and heavy-chain hybrid genes, respectively.
- a cassette vector which contains exons 3-5 of a murine I-E ⁇ gene and an intron gene fragment from the IS2 of a human DR- ⁇ gene can be used in preparing each of the family of human-polymorphic DR- ⁇ /mouse I-E ⁇ hybrid genes.
- the construction of such a gene is illustrated in Example VI.
- Hybrid genes formed in accordance with the foregoing methods can be expressed in a variety of cell systems.
- For the expression of hybrid immunoglobulin genes production of functional immunoglobulin genes by mouse myeloma cell lines (reference 1) and plasmacytoma and raouse-hybridoma cell lines (reference 19) have been shown in cells transfected with cloned immunoglobulin chain genes.
- a cell used in expressing hybrid immunoglobulin genes is preferably one which is compatible with the enhancer element contained in the hybrid gene's intron. Recent studies, referenced above, indicate that the enhancer element functions best when the expression cells are B-lineage cells of the same species from which the enhancer element was derived.
- the expression system will preferably be a B-lineage cell of the same species as that from which the variable region in the gene is derived.
- a mouse cell system such as a plasmacytoma, hybridoma, or myeloma cell line will be preferred.
- a preferred system is murine lymphocyte cells, although other cell lines, such as those suitable for expressing immunoglobulin-chain hybrid genes, may also be used (references 20, 21).
- Murine lymphocyte cells are especially advantageous in expressing hybrid human/mouse immune response genes which are to be used to generate murine monoclonal antibodies directed against each of a variety of human polymorphic regions of cell-surface antigens.
- a hybrid ⁇ or ⁇ immune response gene is transfected into mouse lymphocytes. Expression of the hybrid ⁇ or ⁇ chain leads to association of that chain with the complementary mouse ⁇ or ⁇ chain produced normally by the cell, leading to expression of a hybrid cell-surface antigen.
- Lymphocytes expressing the composite gene are then used to immunize mice of the donor strain.
- the principal foreign immune response antigens in these cells are those coded by the human polymorphic coding region of the hybrid gene.
- Transfection of the selected expression system cells with the hybrid-gene phage, or other suitable transfection vector is carried out by known methods.
- One standard technique involves calcium phosphate-precipitated, DNA-mediated gene transfer (reference 22).
- Protoplast fusion is an alternative procedure that may give greater transfection efficiency in some cells (reference 23).
- a relatively recent procedure relies on strong-voltage fluctuations to increase the permeability of the cells to the transfecting vector (reference 24).
- the efficiency of transfection can be monitored by cotransfection with a selectable-marker plasmid carrying a bacterial antibiotic-resistance gene, such as a neomycin-resistance gene (reference 25).
- a selectable-marker plasmid carrying a bacterial antibiotic-resistance gene such as a neomycin-resistance gene (reference 25).
- Coinfection with a plasmid containing an antibiotic resistance-selectable marker also allows for selection for cells which have been transfected by the hybrid gene vector, since cotransfection of the cell by the phage DNA and selectable-marker plasmid occurs with a high probability.
- the level of hybrid gene transcription and expression can be determined by known hybridization and antibody precipitation techniques, respectively, under conditions in which radiolabeled transcripts and polypeptides are produced.
- the production of functional hybrid antibodies can be monitored, of course, by immunospecific reaction with selected antigens.
- the production of hybrid histocompatibility genes containing polymorphic human class I or class II regions can be confirmed by the ability of the antigens, typically cell bound, to induce human-specific antibodies. From the foregoing, it can be appreciated how various objects of the invention are met.
- the method of the invention allows for the construction, using a single cassette vector, of families of hybrid genes, in which the members of the families are polymorphic in the region of hybrid gene complementary to a coding region contained in the cassette vector.
- Each member of the family can be prepared from library genomic DNA, rather than from isolated cloned gene fragments, and gene construction avoids in vitro restriction cutting and splicing steps. The effort required to obtain hybrid genes, and particular large families of hybrid genes, is thus greatly reduced. Further, the formation of a hybrid gene according to the method of the invention is readily detectable, and the hybrid gene easily isolated, e.g., from plaque-forming phage.
- Site specific DNA cleavage is performed by treating with the suitable restriction enzyme (or enzymes) under conditions which are generally understood in the art, and the particulars of which are specified by the manufacturer of these commercially available restriction enzymes. See, e.g., New England Biolabs, Product Catalog. In general, about 1 ⁇ g of plasmid or DNA sequence is cleaved by one unit of enzyme in about 20 ⁇ l of buffer solution; in the examples herein, typically, an excess of restriction enzyme is used to ensure complete digestion of the DNA substrate.
- Restriction cleaved fragments may be blunt ended by treating with the large fragment of E. coli DNA polymerase I (Klenow) in the presence of the four deoxynucleotide triphosphates (dNTPs) using incubation times of about 15 to 25 minutes at 20 to 25°C. in 50 mM Tris-HCl, pH 7.6. 50 mM NaCl, 6 mM MgCl 2 , 6 mM DTT and 5-10 ⁇ M dNTPs. The Klenow fragment fills in at 5' sticky ends and chews back protruding 3' single strands, even though the four dNTPs are present.
- E. coli DNA polymerase I Klenow
- dNTPs deoxynucleotide triphosphates
- selective repair can be performed by supplying only a selected one or more dNTPs within the limitations dictated by the nature of the sticky ends.
- the mixture is extracted with phenol/chloroform and ethanol precipitated.
- Treatment under appropriate conditions with S1 nuclease results in hydrolysis of any single-stranded portion.
- Synthetic oligonucleotides may be prepared by the triester method of Matteucci, et al (reference 27), or the diethylphosphoramidite method of Caruthers, described in U.S. Patent No. 4,415,732, issued 15 November 1983.
- Ligations are performed typically in 15-30 ⁇ l volumes under the following standard conditions and temperatures: 50 mM Tris-Cl, pH 7.5, 10 mM MgCl 2 , 10 mM DTT, 100 ⁇ g/ml BSA, 1 mM ATP, and either 0.01-0.02 (Weiss) units T4 DNA ligase at 0°C (for "sticky end” ligation) or 0.3-0.6 (Weiss) units T4 DNA ligase at 14°C (for "blunt end” ligation). Intermolecular "sticky end” ligations are usually performed at 33-100 ⁇ g/ml total DNA concentrations (5-100 nM total end concentration).
- Intermolecular blunt end ligations are performed typically at about 1 ⁇ M total ends concentration.
- the vector fragment is commonly treated with calf intestine phosphatase (CIP) in order to remove the 5' phosphate and prevent religation of the vector.
- CIP digestions are conducted typically at about pH 9, in approximately 50 mM Tris, in the presence of Zn +2 and Mg +2 , using about 0.01 unit of CIP per ⁇ g of vector, depending on size, at 37°C for about one hour.
- the preparation is extracted with phehol/chloroform and ethanol precipitation. Alternatively, religation can be prevented in vectors which have been double digested by additional restriction enzyme digestion of the unwanted fragments.
- Example I Constructing a Mouse/Human ⁇ -Chain Cassette Vector This example describes the construction of a plasmid designed for use in preparing mouse/human ⁇ -chain genes.
- Human germline ⁇ gene was originally obtained from a BamHI phage library of human DNA, as described in reference 29, and subcloned into the EcoRI site of PBR322, to form a pHuC vector, whose ⁇ -gene insert is shown at A in Figure 3.
- the pHuC plasmid was digested to completion with EcoRI, and the 2.5 kb fragment containing the constant coding region C ⁇ was isolated by electrophoresis and elution from an agarose gel.
- a ⁇ anl3 plasmid used in constructing the cassette vector was constructed according to procedures similar to those outlined in reference 6 and can be obtained from Dr. Seed.
- Figure 3 includes a 645 base-pair origin of replication from pMBl, a 198 base-pair synthetic tyrosine tRNA suppressor gene, and the polylinker region shown in expanded scale in the figure.
- the plasmid was linearized by treatment with EcoRI, treated with calf intestinal phosphatase to remove 5'-phosphate, and the 0.9 kb plasmid fragment was purified by electrophoresis and elution from agarose gel.
- the 2.5 kb EcoRI C ⁇ fragment from pHuC ⁇ and the 0.9 kb linearized ⁇ plasmid fragment were ligated with T4 DNA ligase, and the ligation products were used to transform E. coli strain MC1061 (P3).
- the bacterium harbors a P3 plasmid having amber mutations in both ampicillin- and tetracycline-resistance genes. Transformation of cells already carrying P3 with the ⁇ anl3 plasmid thus confers simultaneous resistance to ampicillin and tetracyline to these cells.
- a kanamycin-resistance gene in the P3 plasmid is used in maintaining the plasmid in the host in the absence of the ⁇ plasmid.
- An IS2 gene fragment from a mouse ⁇ gene was derived from a pBHC cloning vector containing a Hindlll/BamHI segment of mouse ⁇ gene contained in a pBR322 plasmid (reference 12).
- a map of the ⁇ -gene fragment insert is shown at D in Figure 3.
- the pBHC plasmid was digested to completion with HindiII and XmnI, and the 1 kb fragment which contains the enhancer element in the ⁇ -gene IS2 region was purified by ele ⁇ trophoresis and elution from agarose gel.
- the ⁇ C ⁇ plasmid was prepared by alkaline lysis and digested with Hindlll/Smal, releasing a small Hindlll/Smal fragment from the polylinker region of the plasmid.
- the larger linearized ⁇ -plasmid fragment was purified by electrophoresis and elution from agarose gel. This fragment was ligated to the 1 kb Hindlll/XmnI fragment from pBHC ⁇ with T4DNA ligase, and the ligation products were used to transform
- Lane 1 again represents Hindlll fragments of wild type ⁇ DNA.
- the 2.4 kb and 2.0 kb fragments also correspond to the expected sizes from the ⁇ LC ⁇ construct shown in Figure 3.
- a NotI site was then introduced into plasmid ⁇ LC ⁇ .
- the plasmid was linearized by digestion at the single Hindlll site shown at E in Figure 3.
- the 4.4 kb linear fragment was purified and blunt ended by filling in with Poll-Klenow fragments.
- Kinased NotI linkers (Adapter AB, Figure 12 and Example VII) were then ligated to the blunt ends, followed by digestion with NotI.
- the resulting linear fragment with NotI sticky ends was recircularized and used to transform MC1061(P3) cells. Transformants were selected for the presence of Sup, and plasmid structure verified by cutting with NotI.
- a plasmid, designated ⁇ LC ⁇ .NotI ( Figure 13) was recovered.
- Example II Constructing a Mouse/Human Hybrid ⁇ Gene
- ChC ⁇ -1 containing an EcoRI ⁇ -gene insert from a Balb/c mouse germline cell, was obtained (reference 30).
- the vector contains amber-mutated A and B phage genes, and the EcoRI ⁇ -gene insert extends from a position upstream from the 3' end of the gene through a portion of the constant C ⁇ region.
- MC1061 host cells harboring either the P3 plasmid alone, designated MC1061(P3), or harboring both the P3 plasmid and the ⁇ -plasmid cassette from Example I, designated MC1061(P3) ( ⁇ LC ⁇ ) were preabsorbed with 10 6 ChC ⁇ -1 phage and plated on LB plates. No plaques were obtained with MC1061(P3), the negative control, demonstrating that the ChC ⁇ -1 phage stock contained no wild type revertants. Confluent lysate was obtained with the MC1061(P3) ( ⁇ LC ⁇ ) cells. The titer of the plate lysate on the Sup + cells was 1.5 x 10 9 phage/ml.
- the expanded phage population was repassaged on a suppressor-minus host strain LG75.
- Re ⁇ ombinant phage which acquired the suppressor-tRNA gene by recombination with the cassette vector were selected by growth.
- the structure of the recombination region of the phage is shown at the bottom in Figure 5.
- the recombination event has produced a hybrid human ⁇ -coding region upstream of the site of recombination and a mouse ⁇ -coding region downstream of the recombination site.
- the titer on the plate lysate for the suppressor-minus strain was 4 x 10 6 phage/ml. Therefore, the recombination frequency between the homologous two regions of the cassette plasmid and the phage was about 3 x 10 -3 .
- the plaques from the LG75 plate were replated on LG75 agarose plates, and a few plaques were picked.
- the DNA from recombinant phages was digested with EcoRI, fractionated by agarose gel electrophoresis, and hybridized to a 32 P-labeled ⁇ anl3 probe, with the results shown in Figure 6.
- Lane 1 shows the autoradiogram pattern for ChC ⁇ -1 DNA
- lanes 2-4 show recombinant phage DNAs selected from three different plaques.
- the probe hybridized to a 2.7 kb EcoRI fragment from the recombinant phage DNAs, confirming the structure shown at the bottom in Figure 5, where the recombination event has introduced an EcoRI site and adjacent suppressor-tRNA gene into the phage ⁇ , to give the 2.7 EcoRI fragment indicated.
- the 5 kb and 2.7 kb Hindlll fragments were also hybridized to the J ⁇ probe ( Figure 19).
- Example III Constructing a Mouse/Human ⁇ 4 Cassette Vector This example describes the contruction of a plasmid designed for use in preparing hybrid mouse/human ⁇ 4 genes.
- Human genomic ⁇ 4 was obtained as described in reference 31, and subcloned into pBR322 to form a p24BRH vector, whose insert construction is shown at the top in Figure 7.
- the insert region contains the ⁇ 4 constant-coding region, indicated at C ⁇ 4 in a 2.0 kb EcoRI/Hindlll fragment.
- the p24BRH plasmid is digested to completion with Hindlll, blunt ended, and then digested to completion with EcoRI.
- the 2.0 kb fragment containing the constant region is isolated by electrophoresis and elution from an agarose gel.
- the ⁇ anl3 plasmid from Example I was linearized by digestion with SacI, blunt-ended with T4 DNA polymerase, then further digested to completion with EcoRI.
- the 0.9 kb plasmid fragment was purified by electrophoresis and elution from agarose gel.
- the 2.0 kb Hindlll/EcoRI C ⁇ 4 fragment from p24BRH and the 0.9 kb linearized ⁇ plasmid fragment are ligated with T4 DNA ligase and the ligation products were used to transform E. coli strain MC106KP3), as described in Example I.
- Plasmid minipreps were analyzed by single digestion with Xbal, PstI and Smal to select plasmids with the 2.0 kb C ⁇ 4 fragment in the proper orientation.
- a restriction map of the selected plasmid, designated ⁇ C ⁇ 4, is shown at the center portion of Figure 7, with the C ⁇ 4 insert and adjacent polylinker segment shown in expanded scale.
- An IS2 gene fragment was derived from a segment of a mouse C ⁇ gene containing a heavy-chain enhancer, E H .
- a map of the ⁇ -gene segment is shown in Figure
- a Ch4A phage carrying germ-line C ⁇ was digested to completion with Xbal, and the 1 kb fragment containing the E H element was purified by electrophoresis and elution from agarose gel.
- the ⁇ C ⁇ 4 plasmid was digested with Xbal, and the linearized ⁇ -plasmid fragment was purified by electrophoresis and elution from agarose gel. This fragment was ligated to the 1 kb Xbal ⁇ -gene fragment with T4 DNA ligase, and the ligation products were used to transform MC1061(P3). Successful transformants were selected as above.
- the expected structure of the heavy gene cassette is illustrated at the bottom in Figure 7.
- cassette vector ⁇ HC ⁇ 4 The final structure of the cassette vector, designated ⁇ HC ⁇ 4, was confirmed by digestion with PstI, which gave expected 2.0 kb, 1.5 kb, and 0.4 kb fragments ( Figure 8) and by double digestion with Smal and EcoRI. which yields expected 1.8, 1.77, and 0.3 kb fragments.
- a NotI site was introduced into cassette vector ⁇ HC ⁇ 4 by the procedure described in Example I.
- the phage vector which is shown at the top in Figure 9, contains amber-mutated phage genes, and the ⁇ -gene insert extending from a position upstream of the 3' end of the gene through the constant C ⁇ region.
- MC1061(P3) ( ⁇ HC ⁇ 4), is preabsorbed with 10 6 ChC ⁇ 27 phage and plated on LB plates.
- the expanded phage population is repassaged on a suppressor-minus host strain LG75, and recombinant phage which have acquired the suppressor-tRNA gene by recombination with the cassette vector are selected by growth.
- the structure of the recombinant region of the phage is shown at the bottom in Figure 9.
- the recombination event produces a hybrid gene with murine J H coding regions upstream of the IS2 recombination site and human ⁇ 4-gene coding regions downstream of the recombination site.
- the plaques from the LG75 plate are replated on
- DNA from recombinant phages are analyzed by digesting with EcoRI and hybridized to a 32 P-labeled ⁇ anl3 probe, to confirm the presence of the expected 3.9 kb fragment produced by the recombination event.
- Example V Constructing a Human PR/Mouse I-E Heavy-Chain Cassette Vector
- the murine I-E ⁇ chain gene is isolated following the procedure in reference 8. Briefly, the identified gene clone is grown up in a phage vector, then cloned into pBR322. The I-E ⁇ gene fragment, containing exon 2 through the 3' end of the gene is shown at A in Figure 10.
- a genomic DNA library of mouse-tissue DNA generated by partial Sau3a digestion and cloned into ⁇ , could be screened with synthetic oligonucleotide probes made using the published sequence for the I-E ⁇ gene to select the same gene, and be confirmed by limited sequence analysis.
- a ⁇ anl3 plasmid (Example I) is linearized by digestion with EcoRI and PstI, and the 0.9 kb plasmid fragment is purified by electrophoresis and elution from agarose gel.
- the I-E ⁇ -gene vector from above is digested to completion with PstI and EcoRI and the 2.5 kb fragment and the 0.9 kb linearized ⁇ -plasmid fragment are ligated with T4 DNA ligase.
- the ligation products are used to transform E. coli strain MC1061 (P3).
- a human DR- ⁇ chain gene shown at D in Figure 10, is isolated according to the procedure of reference 13.
- the gene includes a 491 bp intron 2 having the restriction sites indicated in expanded scale in the figure.
- the plasmid carrying the DR- ⁇ gene fragment is digested to completion with Rsal and EcoRV, yielding a 272 bp intron 2 fragment which is purified by electrophoresis and elution from agarose gel. EcoRI linkers are then ligated to the 272 base pair Rsal-EcoRV fragment and then the fragment is digested with EcoRI.
- the ⁇ l-E ⁇ plasmid is digested with EcoRI, phosphatased and the linearized ⁇ -plasmid fragment is purified by electrophoresis and elution from agarose gel. This fragment is ligated to the 280 bp linkered fragment from the DR- ⁇ gene with T4 DNA ligase, and the ligation products are used to transform MC1061 (P3). Successful transformants are selected as above and the orientation of the 280 base pair fragment is confirmed using Ncol.
- the final structure of the MHC heavy-chain gene cassette, seen at E in Figure 10 and referred to as ⁇ DR/I-E ⁇ , is confirmed by digestion with EcoRI, giving expected 280 and 3400 fragments, and by double digestion with PstI and Ncol, giving expected 1110 and 2570 bp fragments.
- a human EBV transformed lymphoblast line is obtained from the subject of interest by standard means.
- the cells are cultured under standard conditions.
- Genomic DNA is extracted from the cells and partially digested with Sau3a.
- the digest fragments are ligated into ⁇ EMBL 3a under standard conditions followed by in vitro packaging and plating on the appropriate bacterial host.
- the library phage vectors are passed initially in MC1061 cells harboring both the P3 plasmid (Example I) and the ⁇ DR/I-E ⁇ cassette vector from Example V.
- the expanded phage population is repassaged on a suppressor-minus host, strain LG75, and recombinant phage which have acquired the suppressor-tRNA gene by recombination with the cassette vector are selected by growth.
- the structure of the recombinant region of the phage is shown at the bottom in Figure 11. As seen, the recombination event produces a hybrid gene with exons 1 and 2 of the human DR- ⁇ gene upstream of the IS2 recombination site, and exons 3-5 of a mouse I-E ⁇ gene downstream of the recombination site.
- a plaque from the LG75 plate is expanded on LG75 agarose plates. DNA from these recombinant phages are analyzed by hybridization to a 32 P-labeled DR- ⁇ exonl probe, to confirm the presence of the expected DR- ⁇ exonl fragment produced by the recombinant event.
- Example VII Construction of Phage Vector ⁇ GLla The following example describes the construction of ⁇ GLla, an improved ⁇ phage vector for the construction of gene libraries for use with the cassette vectors of the present invention.
- Adapter AB oligonucleotide, shown in Figure 12, was synthesized by Applied Biosystems, Foster City, CA. It is a NotI linker molecule also containing an inactivated EcoRI site, and active Xhol and BamHI sites. Adaptor AB is kinased in the presence of ⁇ - 32 P-ATP. The purified stuffer is then ligated to excess adapter AB at 22°C for 1 hr.
- Recombinant phages which lack the stuffer fragment from Ch4a form colorless plaques. Phage DNA from colorless plaques were isolated, and subjected to enzyme restriction analysis by digestion with NotI. A recombinant phage that gave the expected 20 kb, 14 kb, and 11kb fragments was designated ⁇ GLla.
- Example II This example describes the construction of a plasmid designed for use in preparing hybrid mouse/human ⁇ 1 genes.
- ⁇ anl3 (Example I) was linearized with Hindlll and a NotI site inserted as described for plasmid irLC ⁇ in Example I to give the structure B shown in
- Figure 15 ⁇ anl3.NotI was then digested with Xba and ligated to the enhancer fragment E H recovered from ⁇ HC ⁇ 4 ( Figure 7). Recircularized plasmid DNA was then used to transform MC1061(P3) cells and plasmids from transformants analyzed for proper orientation of the E H fragment by digestion with EcoRI. A plasmid designated ⁇ E H .NotI, shown as structure C in Figure 15, gave the expected fragment sizes of 330 and 1570 bp.
- Plasmid 13AHP containing human genomic C ⁇ 1 in pBR322 (reference 34) was obtained from Dr. Jay Ellison. After digesting 13AHP with Hindlll and PvuII, the 3.0 kb fragment containing C ⁇ 1 was purified and the ends trimmed back. Kinased Sst-1 linkers were ligated to the blunt ends of the 3.0 kb fragment, followed by digestion with Sst-1. ⁇ E H .NotI was digested with Sst-1 and ligated to the Sst-1-digested C ⁇ 1 fragment to recircularize as shown in Figure 15.
- the ligated DNA was used to transform MC1061(P3) cells and transformants were analyzed for plasmids containing C ⁇ 1 in the proper orientation.
- the orientation was tested by digestion with PstI alone, and with a combination of PstI and EcoRI.
- ⁇ anl3 (Example I), which had previously been linearized with SacI, sticky ends trimmed and the 5' ends dephosphorylated.
- ⁇ anl3 containing the C ⁇ 3 coding sequences was used to transform MC1061(P3) cells and transformants selected to determine the orientation of the insert.
- a plasmid designated ⁇ C ⁇ 3-14 was obtained with the C ⁇ 3 insert in the wrong orientation.
- ⁇ C ⁇ 3-14 aquired an unexpected additional EcoRI site.
- the orientation of the C ⁇ 3 insert was determined by double digestion with Hindlll + Bglll, which gave the following size fragments: Hindlll + Bglll - 1800 and 2300 bp.
- ⁇ rC ⁇ 3-14 then was digested with EcoRI and religated to reorient the C ⁇ 3 segment.
- Plasmids from transformants were then tested again for correct orientation.
- a plasmid designated ⁇ C ⁇ 3, structure C in Figure 16, gave fragments of the correct size: Hindlll + Bglll - 900 and 3200 bp.
- ⁇ C ⁇ 3 was digested with Xba and the 1 kb -
- Xba fragment of enhancer E H was inserted as described in Example VIII. These recombinant plasmids were used to transform MC1061(P3) cells. Transformants were then tested for the presence of plasmid containing enhancer region in the proper orientation.
- a plasmid designated ⁇ HC ⁇ 3, structure D in Figure 16 was digested with EcoRI and gave fragments of the correct size: 3200, 1600, and 340 bp.
- a NotI site was inserted in the Hindlll site of ⁇ HC ⁇ 3 as described in Example I. This gave a plasmid designated ⁇ HC ⁇ 3.NotI, shown as structure E in Figure 16.
- Switching Cassette Vector for IgM to IgG 3 This example describes the construction of a plasmid designed for use in changing the isotype of a human immunoglogulin heavy chain gene.
- the cassette vector is useful for changing the isotype of an IgM antibody to IgG 3 .
- Plasmid PJ is digested with Bglll and Hindlll, and the 0.75 kb fragment, which contains the intron IS, is purified.
- the ligation mixture was used to transform MC1061(P3) cells and a plasmid designated pHC-1 was recovered (structure D in Figure 17).
- the C ⁇ 3-containing 3.2 kb fragment from Ch4a (Example IX) with added Hindlll linkers was then inserted into the Hindlll site of pHC-1.
- MC1061(P3) cells were transformed by the ligation mixture and transformants tested for the presence of plasmids with the proper orientation by digestion with Bglll.
- a NotI site (adapter AB, Example I) was ligated between the EcoRI and BamHI sites of ⁇ SWMG3 to give a plasmid designated ⁇ SWMG3.NotI, depicted as structure F in Figure 17.
- Cassette Vector for IgM to IgGl This example describes the construction of a cassette vector similar to the one constructed in the previous example, however, it switches IgM to IgG 1 .
- the procedure used to construct this cassette vector is substantially the same as that described in Example X, except that rather than inserting the 3.2 kb C ⁇ 3 fragment into pHC-1, the 3.0 kb C ⁇ 1 fragment described in Example VIII ( Figure 15) with added Hindlll linkers was inserted to give a plasmid designated ITSWMGI (structure A in Figure 18).
- a NotI site was inserted as described in Example X to give a plasmid designated ⁇ SWMGl.NotI (structure B in Figure 18).
- FIG 19 shows the restriction map of the J ⁇ -E ⁇ -C ⁇ -region of an unrearranged mouse gene.
- J ⁇ probe and -J ⁇ probes are the 2.7 kb and 0.7 kb Hindlll fragments, respectively.
- the J ⁇ probe is present in both the unrearranged immunoglobulin gene, as well as normally rearranged immunoglobulin genes.
- the -J ⁇ probe is not present in the normally rearranged gene, but is present in the unrearranged gene.
- Figure 20 shows the restriction map of the -J H -E H -C ⁇ - region of the mouse unrearranged heavy chain immunoglobulin gene.
- This example shows the use of the ⁇ LC ⁇ .NotI cassette vector (Example I, Figure 13) and a library from an anti-Leu3 murine hybridoma in ⁇ GLla (Example VII, Figure 12) to construct a hybrid immunoglobulin gene consisting of the murine variable region of the light chain produced by the hybridoma, and the human C ⁇ region from the cassette vector.
- Hybridoma cell line SBC3.5 producing anti-Leu3 antibodies, was obtained from Dr. Edward Engleman, Stanford University.
- the cellular DNA from the hybridoma was extracted and digested with Hindlll. Restriction patterns were analyzed by Southern blot analysis employing the J ⁇ probe ( Figure 19).
- Southern blot analysis showed a 4.2 kb band that was unique to the anti-Leu3 hybridoma when compared to SP2 (fusion partner of the hybridoma) and Balb/c liver DNAs. This suggests that the 4.2 kb band contains the rearranged anti-Leu3 light chain gene.
- Hybridization employing the J H probe indicated that, judging from the intensities of the autoradiograras relative to liver DNA, the copy number of the anti-Leu3 heavy chain gene is much lower than that of the light chain gene.
- Hybridoma DNA was then extracted and partially digested with EcoRI* activity (reference 44) under conditions to give an average fragment size of 15 kb. Size-selected DNA was then ligated into the EcoRI site of ⁇ GLla DNA and packaged. The number of recombinant phage was estimated by Spi selection (reference 42). 1.2 x 10 6 recombinant phage was divided into twelve sublibraries and then amplified on E. coli KM392 (SupF + ). The plate lysates were replated onto MC1061(P3) cells containing cassette vector
- LG-75 to KM392 was 10 -5 to 10 -7 .
- Phage were then screened by hybridization to the J ⁇ probe. Eleven sublibraries of the twelve were positive. J + k SupF phage was then plaque purified, and then hybridized to the J ⁇ , human C ⁇ ( Figure 3A), and -J ⁇ probes to eliminate unrearranged clones. Three of the eleven sublibraries belonged to unrearranged light chain genes as indicated by hybridization to probe -J ⁇ . All of the remaining eight phage clones hybridized to J ⁇ and human C ⁇ probes, suggesting that they contain the right sequences. Primary lysate was prepared from a single plaque. Extracted DNA was confirmed by digestion with the appropriate enzymes, and by hybridization to probes
- Competent MC1061(P3) cells were then transformed with each circular ⁇ plasmid DNA.
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Un vecteur cassette est utilisé pour construire un gène hybride Ai-B' dans lequel (a) Ai est une région polymorphe de codage dérivée d'un gène Ai-Bi appartenant à une famille de gènes polymorphes A-B; (b) B' est dérivé d'un gène A'-B' sélectionné; (c) Ai et A' et Bi et B' sont des régions structurellement et fonctionnellement homologues de codage de gènes; et (d) les régions de codage A et B et les régions de codage A' et B' sont séparées par les introns I et I', respectivement. Le vecteur comprend un gène sélectionnable de marquage qui permet de sélectionner dans un hôte un vecteur de clonage qui acquiert le gène de marquage par recombinaison avec le vecteur cassette, la région B' de codage, et, adjacent à l'extrémité 5' de ladite région B' de codage, un fragment de gène dérivé de l'intron I de l'un des gènes appartenant à la famille de gènes A-B. L'introduction du vecteur et d'une génothèque de fragments d'ADN génomique contenant un fragment de gène Ai-intron dans un hôte recombinable entraîne la recombinaison qui produit le gène Ai-B' voulu. Un vecteur de clonage contenant le gène hybride peut être aisément sélectionné grâce à la présence du gène de marquage sélectionnable du vecteur cassette, incorporé dans le vecteur de clonage lors de la recombinaison. Un vecteur de clonage de phages lambda est utilisé pour construire des génothèques d'ADN génomique utilisables avec les vecteurs cassettes.A cassette vector is used to construct a hybrid gene Ai-B 'in which (a) Ai is a polymorphic coding region derived from an Ai-Bi gene belonging to a family of polymorphic genes A-B; (b) B 'is derived from a selected A'-B' gene; (c) Ai and A 'and Bi and B' are structurally and functionally homologous gene coding regions; and (d) the coding regions A and B and the coding regions A 'and B' are separated by the introns I and I ', respectively. The vector comprises a selectable labeling gene which makes it possible to select in a host a cloning vector which acquires the labeling gene by recombination with the cassette vector, the B 'coding region, and, adjacent to the 5' end of said vector. coding region B ', a gene fragment derived from intron I of one of the genes belonging to the AB gene family. The introduction of the vector and a library of genomic DNA fragments containing an Ai-intron gene fragment into a recombinant host results in the recombination which produces the desired Ai-B 'gene. A cloning vector containing the hybrid gene can be easily selected by virtue of the presence of the selectable labeling gene of the cassette vector, incorporated into the cloning vector during recombination. A lambda phage cloning vector is used to construct genomic DNA libraries for use with cassette vectors.
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71305285A | 1985-03-18 | 1985-03-18 | |
US713052 | 1985-03-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0217916A1 true EP0217916A1 (en) | 1987-04-15 |
EP0217916A4 EP0217916A4 (en) | 1989-02-23 |
Family
ID=24864557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19860902598 Ceased EP0217916A4 (en) | 1985-03-18 | 1986-03-18 | Hybrid-gene cassette vector. |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0217916A4 (en) |
JP (1) | JPS62502586A (en) |
AU (1) | AU596585B2 (en) |
WO (1) | WO1986005513A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3526995A1 (en) * | 1985-07-27 | 1987-02-05 | Hoechst Ag | FUSION PROTEINS, METHOD FOR THEIR PRODUCTION AND THEIR USE |
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5576195A (en) * | 1985-11-01 | 1996-11-19 | Xoma Corporation | Vectors with pectate lyase signal sequence |
AU606320B2 (en) * | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1990012880A1 (en) * | 1989-04-18 | 1990-11-01 | Applied Biotechnology, Inc. | Generation of hybrid genes and proteins by virus-mediated recombination |
WO2000052146A2 (en) | 1999-03-05 | 2000-09-08 | Maxygen, Inc. | Encryption of traits using split gene sequences |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0162319A2 (en) * | 1984-04-24 | 1985-11-27 | Tasuku Honjo | Method of joining heterologous genes |
EP0173494A2 (en) * | 1984-08-27 | 1986-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by DNA splicing and expression |
WO1986001533A1 (en) * | 1984-09-03 | 1986-03-13 | Celltech Limited | Production of chimeric antibodies |
EP0171496B1 (en) * | 1984-08-15 | 1993-05-26 | Research Development Corporation of Japan | Process for the production of a chimera monoclonal antibody |
-
1986
- 1986-03-18 JP JP50206086A patent/JPS62502586A/en active Pending
- 1986-03-18 AU AU56680/86A patent/AU596585B2/en not_active Ceased
- 1986-03-18 WO PCT/US1986/000566 patent/WO1986005513A1/en not_active Application Discontinuation
- 1986-03-18 EP EP19860902598 patent/EP0217916A4/en not_active Ceased
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0162319A2 (en) * | 1984-04-24 | 1985-11-27 | Tasuku Honjo | Method of joining heterologous genes |
EP0171496B1 (en) * | 1984-08-15 | 1993-05-26 | Research Development Corporation of Japan | Process for the production of a chimera monoclonal antibody |
EP0173494A2 (en) * | 1984-08-27 | 1986-03-05 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by DNA splicing and expression |
WO1986001533A1 (en) * | 1984-09-03 | 1986-03-13 | Celltech Limited | Production of chimeric antibodies |
Non-Patent Citations (1)
Title |
---|
See also references of WO8605513A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU5668086A (en) | 1986-10-13 |
AU596585B2 (en) | 1990-05-10 |
WO1986005513A1 (en) | 1986-09-25 |
JPS62502586A (en) | 1987-10-08 |
EP0217916A4 (en) | 1989-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5633425A (en) | Transgenic non-human animals capable of producing heterologous antibodies | |
DE69133476T2 (en) | Transgenic mice capable of producing heterologous antibodies | |
US5874299A (en) | Transgenic non-human animals capable of producing heterologous antibodies | |
CA2124967C (en) | Transgenic non-human animals capable of producing heterologous antibodies | |
Eckhardt et al. | Independent immunoglobulin class-switch events occurring in a single myeloma cell line | |
FI121339B (en) | Genetically engineered mice for the production of human antibodies, and methods for their production | |
KR100855998B1 (en) | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions | |
Siebenkotten et al. | The murine IgG1/IgE class switch program | |
RU2731084C2 (en) | Producing non-human mammalian antibodies | |
US5939598A (en) | Method of making transgenic mice lacking endogenous heavy chains | |
US5338669A (en) | Method of producing fusion proteins | |
EP0765937B1 (en) | Method of producing fusion proteins | |
WO1991000906A1 (en) | Chimeric and transgenic animals capable of producing human antibodies | |
KR20120068757A (en) | Soluble "heavy-chain only" antibodies | |
WO1991016427A1 (en) | Methods for phenotype creation from multiple gene populations | |
JP2619232B2 (en) | Gene system encoding human immunoglobulin E binding factor active polypeptide | |
JPH11206387A (en) | Preparation of immunoglobulin and transgenic mouse therefor | |
AU596585B2 (en) | Hybrid genes (eg. ig's & mhc proteins) via lambda library andplasmid casette vector | |
WO1991010722A2 (en) | Chimeric immunoglobulin for cd4 receptors | |
JPS62269697A (en) | Production of erythropoietin | |
Teillaud et al. | 22. Monoclonal Antibodies | |
EP0344319A1 (en) | Immunoglobulin gene-related dna fragment | |
Smith et al. | Detection of gene targeting by co-conversion of a single nucleotide change during replacement recombination at the immunoglobulin μ hesvy chain locus | |
Rickert | Somatic mutation and affinity maturation in the BALB/c secondary response to influenza virus | |
Morrison et al. | SECTION V IMMUNOLOGIC INTERVENTION WITH MONOCLONAL ANTIBODIES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19861125 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19890223 |
|
17Q | First examination report despatched |
Effective date: 19890807 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 19900826 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: KIM, JUNGSUH, PARK Inventor name: COLLINS, FRANCIS Inventor name: FRY, KIRK Inventor name: WEISSMAN, SHERMAN, M. |